# Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus

> **NCT01406717** · PHASE3 · COMPLETED · sponsor: **Sun Pharmaceutical Industries Limited** · enrollment: 360 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** SPIL1033
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01406717
- **Lead sponsor:** Sun Pharmaceutical Industries Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-01
- **Primary completion:** 2015-11-04
- **Final completion:** 2015-11-04
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2020-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01406717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01406717, "Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01406717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*